This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: National Institute of Health and Medical Research, Université De Paris. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 1,853 
1 out of 68 
Years Active: 2025
Title: Innovations in Immunotherapy: The Contributions of Jean-Christophe Bories
Introduction
Jean-Christophe Bories is a notable inventor based in Paris, France. He has made significant contributions to the field of immunotherapy, particularly in the development of antibodies targeting CD38. His work is particularly relevant in the context of malignant hematological diseases, including multiple myeloma.
Latest Patents
Jean-Christophe Bories holds a patent for "Antibodies having specificity for CD38 and uses thereof." This invention focuses on a new antibody against CD38, which is expressed in various malignant hematological diseases. The patent describes the development of Bi38-3, a bispecific T cell engager that targets CD38 on multiple myeloma cells. Bi38-3 is designed to recruit cytotoxic T cells through the CD3ε, effectively triggering T cell proliferation, cytokine release, and lysis of CD38 positive multiple myeloma cells in vitro. The results indicate that Bi38-3 can eliminate tumor plasma cells isolated from multiple myeloma patients while preserving the integrity of T, B, and NK lymphocytes. Importantly, Bi38-3 has shown efficacy in reducing tumor cells in a xenograft mouse model of human multiple myeloma.
Career Highlights
Throughout his career, Jean-Christophe Bories has worked with esteemed institutions such as Inserm (Institut National de la Santé et de la Recherche Médicale) and Université de Paris. His research has focused on innovative approaches to combat malignant diseases through targeted immunotherapy.
Collaborations
Jean-Christophe has collaborated with notable colleagues, including Armand Bensussan and Maxime Fayon. Their combined expertise has contributed to advancements in the field of immunotherapy.
Conclusion
Jean-Christophe Bories is a pioneering inventor whose work on CD38-targeting antibodies represents a significant advancement in the treatment of multiple myeloma and other hematological malignancies. His contributions to immunotherapy hold promise for improving patient outcomes in the future.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile